HX008 + LP002

HX008 + LP002 is an investigational combination therapy consisting of two humanized monoclonal antibodies—HX008, which targets programmed cell death protein 1 (PD-1), and LP002, which targets programmed death-ligand 1 (PD-L1). The combination is designed to block both the PD-1 and PD-L1 immune checkpoint pathways, which are known to play crucial roles in tumor immune evasion. Evidence indicates that blocking both pathways may produce a synergistic anti-tumor effect in patients with advanced melanoma who have failed previous immune checkpoint inhibitor therapy. HX008 (pucotenlimab) is a humanized IgG4 monoclonal antibody with an engineered Fc domain, while LP002 is a humanized monoclonal antibody directed against PD-L1. Both components are being developed primarily for cancer immunotherapy, with ongoing trials focusing on advanced melanoma[2][3][6].